Photo by janiecbros/E+ via Getty Images
Investors of Gilead Sciences (GILD) must have been pretty disappointed with the stock. The price of Gilead stock is basically at the same levels as it was back in early 2020. The early hype from Remdesivir was unable to push the stock beyond $85. Soon the stock started a downtrend to the level we see it today. I believe though the market is over-looking this company. Let’s dive into the analysis.
Just a brief overview of the company. Gilead is a major biopharmaceutical…
